Bergenbio Asa Stock Fundamentals
| BGBIO Stock | NOK 11.80 0.74 5.90% |
Bergenbio ASA fundamentals help investors to digest information that contributes to Bergenbio ASA's financial success or failures. It also enables traders to predict the movement of Bergenbio Stock. The fundamental analysis module provides a way to measure Bergenbio ASA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bergenbio ASA stock.
Bergenbio |
Bergenbio ASA Company Current Valuation Analysis
Bergenbio ASA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bergenbio ASA Current Valuation | 421.26 M |
Most of Bergenbio ASA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bergenbio ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bergenbio ASA has a Current Valuation of 421.26 M. This is 97.07% lower than that of the Biotechnology sector and 90.93% lower than that of the Health Care industry. The current valuation for all Norway stocks is 97.47% higher than that of the company.
Bergenbio ASA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bergenbio ASA's current stock value. Our valuation model uses many indicators to compare Bergenbio ASA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bergenbio ASA competition to find correlations between indicators driving Bergenbio ASA's intrinsic value. More Info.Bergenbio ASA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bergenbio ASA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bergenbio ASA's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bergenbio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bergenbio ASA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bergenbio ASA could also be used in its relative valuation, which is a method of valuing Bergenbio ASA by comparing valuation metrics of similar companies.Bergenbio ASA is currently under evaluation in current valuation category among its peers.
Bergenbio Fundamentals
| Return On Equity | -0.96 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (383.14) % | |||
| Current Valuation | 421.26 M | |||
| Shares Outstanding | 88.66 M | |||
| Shares Owned By Insiders | 34.95 % | |||
| Shares Owned By Institutions | 19.17 % | |||
| Price To Book | 3.92 X | |||
| Price To Sales | 756.59 X | |||
| Revenue | 774 K | |||
| Gross Profit | 774 K | |||
| EBITDA | (308 M) | |||
| Net Income | (309.36 M) | |||
| Cash And Equivalents | 436.65 M | |||
| Cash Per Share | 5.59 X | |||
| Total Debt | 942 K | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 8.23 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (303.34 M) | |||
| Earnings Per Share | (3.50) X | |||
| Target Price | 20.25 | |||
| Number Of Employees | 34 | |||
| Beta | 1.63 | |||
| Market Capitalization | 609.1 M | |||
| Total Asset | 450.24 M | |||
| Net Asset | 450.24 M |
About Bergenbio ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bergenbio ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bergenbio ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bergenbio ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. The company was founded in 2007 and is headquartered in Bergen, Norway. BerGenBio ASA is traded on Oslo Stock Exchange in Norway.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bergenbio Stock
Bergenbio ASA financial ratios help investors to determine whether Bergenbio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bergenbio with respect to the benefits of owning Bergenbio ASA security.